MX2022003820A - Metodos de tratamiento para modificar la hermodinamica. - Google Patents

Metodos de tratamiento para modificar la hermodinamica.

Info

Publication number
MX2022003820A
MX2022003820A MX2022003820A MX2022003820A MX2022003820A MX 2022003820 A MX2022003820 A MX 2022003820A MX 2022003820 A MX2022003820 A MX 2022003820A MX 2022003820 A MX2022003820 A MX 2022003820A MX 2022003820 A MX2022003820 A MX 2022003820A
Authority
MX
Mexico
Prior art keywords
treatment
human subject
hemodynamics
modifying
methods
Prior art date
Application number
MX2022003820A
Other languages
English (en)
Inventor
Roelof Peter Pickkers
Gert Wensvoort
Original Assignee
Ebi Anti Sepsis B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ebi Anti Sepsis B V filed Critical Ebi Anti Sepsis B V
Publication of MX2022003820A publication Critical patent/MX2022003820A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención proporciona un método de tratamiento que comprende la administración de un péptido AQGV, o un análogo funcional del mismo, a un sujeto humano, donde el sujeto humano opcionalmente tiene una función renal deteriorada, en donde el tratamiento para administrar un péptido AQGV comprende mantener o mejorar la estabilidad hemodinámica en el sujeto humano, como un sujeto humano que padece o se considera que padece la enfermedad de Clarkson (CLS).
MX2022003820A 2019-09-30 2020-09-30 Metodos de tratamiento para modificar la hermodinamica. MX2022003820A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962908442P 2019-09-30 2019-09-30
US202063045752P 2020-06-29 2020-06-29
PCT/NL2020/050605 WO2021066649A1 (en) 2019-09-30 2020-09-30 Methods of treatment for modifying hemodynamics

Publications (1)

Publication Number Publication Date
MX2022003820A true MX2022003820A (es) 2022-09-19

Family

ID=72811922

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003820A MX2022003820A (es) 2019-09-30 2020-09-30 Metodos de tratamiento para modificar la hermodinamica.

Country Status (10)

Country Link
US (1) US20220370543A1 (es)
EP (1) EP4037701A1 (es)
JP (1) JP2023503790A (es)
KR (1) KR20220106114A (es)
AU (1) AU2020360113A1 (es)
CA (1) CA3152346A1 (es)
CL (1) CL2022000786A1 (es)
CO (1) CO2022005113A2 (es)
MX (1) MX2022003820A (es)
WO (1) WO2021066649A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023521744A (ja) * 2020-04-06 2023-05-25 バイオテンプト ビー．ブイ． 感染症における血行動態を変更する為の方法及び手段
EP4221737A1 (en) * 2020-09-30 2023-08-09 Biotempt B.V. Autophagy-inhibiting peptide and organic acid salt thereof addressing issues of vascular permeability
AU2022359382A1 (en) * 2021-10-05 2024-05-02 Biotempt B.V. Angiogenic control, preferably combined with glycaemic control.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1466612A1 (en) * 2003-04-08 2004-10-13 Biotempt B.V. Treatment of inflammation and sepsis with hCG derived peptides
PL2120991T3 (pl) * 2007-02-12 2014-07-31 Biotempt Bv Leczenie urazów krwotocznych krótkimi oligopeptydami
WO2009014440A1 (en) * 2007-07-23 2009-01-29 Biotempt B.V. Inhibition of renal ischemia reperfusion injury by synthetic oligopeptides

Also Published As

Publication number Publication date
CA3152346A1 (en) 2021-04-08
WO2021066649A1 (en) 2021-04-08
EP4037701A1 (en) 2022-08-10
CO2022005113A2 (es) 2022-06-21
CL2022000786A1 (es) 2022-11-04
KR20220106114A (ko) 2022-07-28
US20220370543A1 (en) 2022-11-24
AU2020360113A1 (en) 2022-04-14
JP2023503790A (ja) 2023-02-01

Similar Documents

Publication Publication Date Title
MX2022003820A (es) Metodos de tratamiento para modificar la hermodinamica.
EA200501891A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
DK1613347T3 (da) Humaniserede antistoffer, der genkender beta-amyloidpeptid
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
EA200601671A1 (ru) Идентификация собственных и чужеродных антигенов, вовлечённых в аутоиммунные заболевания
EA202192625A1 (ru) Лиганды псевдокиназы tyk2
EA200801310A1 (ru) Фармацевтические препараты и их применение при лечении половой дисфункции у женщин
MX2021008207A (es) Proteínas de fusión multifuncionales y usos de las mismas.
EA202191175A1 (ru) Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
NO20055309D0 (no) Slurp-1 samrnensetninger og fremgangsmater for anvendelse derav
WO2020132658A3 (en) Tubulysins and protein-tubulysin conjugates
MX2022001841A (es) Anticuerpos contra ilt2 y uso de los mismos.
MX2019002382A (es) Anticuerpos anti-gremlin-1 (grem1) y metodos de uso de los mismos para tratar la hipertension arterial pulmonar.
WO2020180712A8 (en) Anti-tnfr2 antibodies and uses thereof
EA200501620A1 (ru) Лечение состояний, включающих амилоидные бляшки
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
MX2021008081A (es) Tratamiento de la enfermedad de sjogren con proteinas de fusion de nucleasa.
MX2020009305A (es) Uso de un anticuerpo anti-p-selectina.
EA200601392A1 (ru) Способы и композиции для лечения липодистрофии
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
MX2022015769A (es) Tubulisinas y conjugados de proteina-tubulisina.
MX2023001055A (es) Inmunógenos derivados de la proteína de la espícula del sars-cov2.
WO2020086479A9 (en) Dosing
MX2021011183A (es) Fitoecdisonas y los derivados de las mismas para su uso en el tratamiento de la alteracion de la funcion respiratoria.
MX2020008262A (es) Tratamiento del síntoma más molesto (smm) asociado a la migraña usando anticuerpos anti-cgrp.